These approvals will change the paradigm for treating cancer patients,” Narasimhan says. The medicine now approved for use ...

Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health.

Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at their medium- to long-term outlook.” ...

Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings. Coca-Cola on ...

May 8, 2025 – Today, TIME reveals the second annual TIME100 Health list recognizing the 100 most influential individuals in ...

The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals get in the way of its progress. With recent indication additions, breast ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...